{"filings":[{"id":2243918,"accession_number":"0001193125-26-349136","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2026-08-13T20:04:52+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q2 2026 revenue down 17.5% to $3.0M; adjusted EBITDA turns negative","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.0M, down 17.5% YoY from $3.6M; gross margin 48.6% vs 50.9% prior year.","Operating loss widened to $0.3M from $0.1M; adjusted EBITDA turned negative at -$0.1M vs +$0.1M.","Cash balance $0.3M; operating expenses cut 11.3% YoY to $1.7M.","44% of net revenue from new products launched since Jan 2023; 52 new products launched; launched PlusHLTH.com e-commerce.","U.S. Senate voted 61-32 on H.R. 6500 delaying restrictive hemp-derived cannabinoid provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":861278,"accession_number":"0001193125-26-257417","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2026-06-04T20:14:44+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CV Sciences shareholders reject reverse stock split; three directors elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal 2 (reverse stock split up to 1-for-800) failed: 48.5M for, 59.6M against, 8.1M abstain.","Directors elected: Dr. Jamie Corroon (39.5M for), Joseph Dowling (37.7M for), Bill McCorkle (22.7M for, 17.2M abstain).","Ratification of Haskell & White as auditor passed with 102.4M for vs 12.5M against.","Quorum of 60.1% achieved with 116.2M shares represented at the virtual annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442478,"accession_number":"0001193125-26-223967","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2026-05-14T20:04:49+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q1 revenue down 11.4% to $3.2M; adjusted EBITDA loss narrows to $0.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.2M (down 11.4% YoY); unit sales down 12.2%, partially offset by minor price increases.","Gross margin improved to 48.9% (from 46.0% YoY); operating loss $0.3M vs prior year operating income due to $0.5M payroll tax reversal.","Adjusted EBITDA loss of $0.1M vs $0.3M loss in Q1 2025; cash balance $0.3M at quarter end.","Completed debt restructuring to strengthen financial position; launched EMPOWR plant-based protein/creatine formula.","New products launched since Jan 2023 contributed 43% of Q1 net revenue; 45 new products introduced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93296,"accession_number":"0001193125-26-151228","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"CV Sciences issues $99,614 senior secured convertible note; conversion price cut to $0.03","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $99,614.04 senior secured convertible note due July 6, 2027 to an institutional investor.","April 9, 2026 amendment reduced fixed conversion price on prior notes from $0.06 to $0.03 per share.","Third Note conversion price fixed at $0.03 (lesser of $0.03 and prior-day closing price of $0.04).","No interest accrues unless Event of Default; then 18% late fee per annum applies.","Conversion subject to 4.99% beneficial ownership limitation (can be increased to 9.99%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104794,"accession_number":"0001193125-26-126211","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences FY2025 revenue down 12% to $13.8M; adjusted EBITDA loss narrows to $0.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $13.8M for FY2025 vs $15.7M in 2024, a 12.2% decline on lower volume and regulatory headwinds.","Gross margin improved to 49.0% from 45.6%; operating loss reduced to $0.5M from $2.2M.","Adjusted EBITDA loss was $0.3M, improved from $0.8M in 2024; Q4 2025 delivered positive adjusted EBITDA of $0.1M.","Cash balance $0.3M at year-end; completed debt restructuring in Q1 2026 to strengthen financial position.","Launched 39 new products since Jan 2023; new products contributed 39% of FY2025 net revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104793,"accession_number":"0001193125-26-100436","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"CV Sciences restructures notes: adds conversion at $0.06/share, principal to $2.256M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Outstanding note principal increased 20% to $2,256,000; monthly redemption obligation eliminated.","Added conversion feature at $0.06/share, initially convertible into 37.6M shares of common stock.","True-up provision requires additional note if net proceeds from conversion sales fall short of principal.","Company paid $15,000 documentation fee; beneficial ownership cap set at 4.99% (can be raised to 9.99%).","Management says restructuring strengthens balance sheet and positions for sustained profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121077,"accession_number":"0001193125-25-280116","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q3 revenue $3.3M (-16% YoY); adjusted EBITDA loss $118K; hemp regulatory language enacted with 1-yr delay","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.3M, down 16% YoY from $3.9M; net revenue from products launched since Jan 2023 contributed 39%.","Gross margin 48.5% (Q3 2024: 46.0%; Q2 2025: 50.9%); adjusted EBITDA loss $118K vs $75K loss in Q3 2024.","Cash balance $0.4M at quarter-end; launched +PlusCBD Ignite men's formula. Federal hemp language enacted with one-year delay."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":10482000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121076,"accession_number":"0001193125-25-237188","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CV Sciences issues $600K secured note with $300K net proceeds; potential add'l $750K","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $600K secured promissory note with 25% OID ($150K) plus $150K modification fee; net proceeds $300K.","Note matures April 6, 2027; monthly principal payments of $46,153.85 begin April 6, 2026.","Note secured by all company assets and IP; customary default provisions with 18% default interest.","Potential additional $750K note upon consummation of Extract Labs acquisition on terms satisfactory to investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137698,"accession_number":"0001193125-25-207436","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CV Sciences amends $1.6M secured note, extends maturity to 2027, defers payments","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Original $1.6M note issued Feb 2025 with $400K OID; outstanding balance $1.28M after $320K payments.","New maturity date extended to Feb 12, 2027; monthly redemption schedule modified to defer six months.","First 3 months: $106.7K each; next 6 months: $0; subsequent 12 months: $106.7K each plus accrued interest.","Investor receives $150K cash as consideration; agreement contemplates potential additional $450K secured note.","Company paid $10K investor legal fees at origination; amendment includes cash payment of $150K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137697,"accession_number":"0000950170-25-107984","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q2 revenue $3.6M (-8% YoY); first positive adjusted EBITDA in six years","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.6M, down 8% from $4.0M in Q2 2024; units sold down 7%, avg price down 2.8%.","Gross margin 50.9%, highest since Q3 2019, up from 47.0% in Q2 2024.","Adjusted EBITDA positive $0.1M, first since Q2 2019, vs -$6k in Q2 2024.","Cash balance $0.9M at quarter end, up from $0.5M at end of 2024.","CEO cites state regulatory pressure for sales decline; pushing M&A and new products."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":7226000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155083,"accession_number":"0000950170-25-081934","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"CV Sciences annual meeting: directors elected, auditor ratified, say-on-pay approved at 2-year frequency","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 54.6% (100.7M of 184.3M shares); directors Corroon, Dowling, McCorkle elected with 17.0M-32.9M votes for.","Haskell & White LLP ratified as auditor for FY2025: 92.5M for, 6.9M against, 1.3M abstain.","Non-binding advisory vote on executive compensation approved: 28.6M for, 5.4M against, 2.0M abstain.","Advisory vote on frequency: Every 2 years approved (27.4M votes), 1 year (5.1M), 3 years (2.0M), abstain (1.5M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155082,"accession_number":"0000950170-25-071347","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q1 2025 revenue $3.6M (-10% YoY); turns operating profit $11K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $3.6M vs $4.0M YoY; unit volume down 11.8%, partially offset by 0.9% price increase.","Operating income of $11K vs $0.6M loss YoY, boosted by $0.5M reversal of accrued payroll taxes.","Adjusted EBITDA loss improved to $0.3M from $0.5M YoY; gross margin 46.0% vs 46.3%.","Launched Lunar Fox plant-based product line with 7 vegan products in U.S. retail and online.","Raised $1.2M net from institutional investor in Q1; cash balance $0.8M vs $0.5M end-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":3606000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173602,"accession_number":"0000950170-25-045761","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences FY2024 revenue $15.7M (-1.9% YoY), operating loss $2.2M vs income $3.4M in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $15.7M vs $16.0M in 2023; Q4 revenue $3.9M (+2.2% YoY).","Gross margin improved to 45.6% from 44.3%; adjusted EBITDA loss narrowed to $0.8M from $2.3M.","Cash balance $0.5M at year-end vs $1.3M; net proceeds of $0.9M from Streeterville financing in Q3 2024.","Acquired Elevated Softgels in Q2 2024; launched +PlusHLTH brand and Lunar Fox plant-based line.","Retained Maxim Group as non-exclusive financial advisor; evaluating M&A opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173601,"accession_number":"0000950170-25-023618","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CV Sciences issues $1.6M secured promissory note, net proceeds $1.2M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $1.6M with $400K original issue discount, net $1.2M to company.","Monthly payments of $106,666.67 begin June 12, 2025; maturity August 12, 2026.","Note secured by all company assets and intellectual property; interest only accrues on default.","Early repayment in full by August 13, 2025 qualifies for $100K discount.","Proceeds used to pay off existing Streeterville Capital debt and for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173600,"accession_number":"0000950170-25-022630","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CV Sciences initiates arbitration against former legal counsel Procopio over faulty RSU tax advice","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Arbitration filed Feb 12, 2025; claims Procopio provided incorrect tax advice on CEO Mona's RSU settlement.","Shares valued >$13M were issued to Mona without tax withholding based on Procopio's guidance.","Procopio later reversed its advice and terminated representation on Jan 10, 2025.","Company seeks damages including fees and expenses from reliance on the faulty advice.","Lack of withholding has been disclosed in SEC filings since Q1 2019 and led to prior litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173599,"accession_number":"0000950170-25-018048","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["1.02","1.01"],"status":"ready","headline":"CV Sciences disputes Extract Labs acquisition termination by Sellers; evaluating options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Feb 5, 2025, Extract Labs owners informed CV Sciences they cannot close due to alleged failure to obtain bank consent, purportedly terminating the Stock Purchase Agreement.","CV Sciences disputes the Sellers' right to terminate and reserves all rights; evaluating legal options.","The Purchase Agreement was entered on Nov 21, 2024, for CV Sciences to acquire all outstanding shares of Extract Labs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190578,"accession_number":"0000950170-24-130576","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CV Sciences prevails in arbitration against former executive Michael Mona Jr.","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["On Nov 20, 2024, arbitrator ruled in favor of CV Sciences and management, denying all claims by Mona.","Mona had sought recovery of taxes, interest, and penalties from RSU vesting in 2019, alleging breach of contract.","Arbitration began April 8, 2024, concluded May 23, 2024; award received Nov 20, 2024.","Case originated from a Nevada state court complaint filed Nov 5, 2021, later ordered to arbitration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190577,"accession_number":"0000950170-24-129750","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"CV Sciences agrees to acquire Extract Labs for $1.4M cash and stock, plus earnout","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration: $400K cash + $1M in CVSI stock at closing; up to $600K earnout in stock.","Earnout tied to Extract Labs revenue targets: $3.5M-$4.6M per 12-month period for two years.","Acquisition expected to close in Q1 2025, subject to customary conditions.","CV Sciences plans to in-source +PlusCBD production, citing cost savings and supply chain control.","Extract Labs described as stand-alone profitable, GMP-certified, and FDA-registered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190576,"accession_number":"0000950170-24-126787","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q3 2024 revenue $3.9M, gross margin 46%, adjusted EBITDA loss of $75k","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.9M, down 5% YoY from $4.1M; B2B sales fell 9% due to state CBD regulations.","Gross margin improved to 46.0% from 45.1% YoY; operating loss narrowed to $0.3M from $0.4M.","Adjusted EBITDA loss of $75k, near breakeven versus $0.4M loss a year ago.","Cash balance $1.0M at quarter end; secured $0.9M net proceeds from Streeterville financing.","Launched +PlusHLTH supplement line (CLARITY, PEACE, RESHAPE) and new pet chews."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":11821000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207073,"accession_number":"0000950170-24-095801","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q2 2024 revenue flat at $4.0M; gross margin improves to 47%, adjusted EBITDA near breakeven","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.0M flat YoY and sequentially; B2C sales up 4% offset by B2B decline of 3%.","Gross margin 47.0% vs 43.3% YoY, best in 13 quarters; operating loss narrowed to $0.6M from $1.1M.","Adjusted EBITDA loss just $6,000, near cash-flow breakeven; cash balance $0.5M vs $1.3M year-end 2023.","Closed acquisition of Elevated Softgels in May 2024; appointed Maxim Group as financial advisor for strategic options.","Received net proceeds of $0.9M from Streeterville financing; remains top hemp extract brand per SPINS."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":7956000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207072,"accession_number":"0000950170-24-082225","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CV Sciences enters $1.19M secured note with Streeterville Capital, net proceeds $900K","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal amount $1,188,500; net proceeds $900,000 after $283,500 OID and $5,000 fees.","Weekly repayments of $22,855.77; maturity 12 months from July 3, 2024.","Note secured by all assets; default interest 22% per annum on event of default.","Early repayment discount of $75,000 if paid in full by Dec 31, 2024.","Guaranties from subsidiaries: Star Sky Foods, Cultured Foods Sp. z o.o., Elevated Softgels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224394,"accession_number":"0000950170-24-076955","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CV Sciences enters new 3-year employment agreements with CEO and CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Joseph Dowling new base salary $300K/year, target annual bonus 50% of base.","CFO Joerg Grasser new base salary $235K/year, target annual bonus 20% of base.","Both agreements run through June 20, 2027, with change-of-control severance of 2x base salary.","Dowling has $433,871 in deferred base salary plus $490,274 total accrued (2020-2022).","Dowling eligible for $1,500/month car allowance and $1.5M life insurance paid by company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224393,"accession_number":"0000950170-24-069998","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"CV Sciences stockholders elect directors, ratify auditor, approve exec comp at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum of 53.1% achieved with 86,682,380 shares represented at June 3, 2024 meeting.","Three directors elected: Dr. Jamie Corroon (28,999,412 for), Joseph Dowling (26,074,685 for), Bill McCorkle (28,764,821 for).","Ratification of Haskell & White LLP as auditor for FY2024 passed with 84,248,548 for, 1,837,030 against.","Non-binding advisory vote on named executive officer compensation approved with 20,844,946 for, 9,562,945 against.","All proposals passed with broker non-votes on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224392,"accession_number":"0000950170-24-059152","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q1 2024 revenue $4.0M, gross margin 46.3%, operating loss $0.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.0M, down 4% YoY from $4.1M, up sequentially from $3.8M in Q4 2023.","Gross margin 46.3%, best in 12 quarters, up from 43.0% in Q1 2023.","Operating loss $0.6M vs operating income $5.8M in Q1 2023 (due to reversal of accrued payroll tax of $6.2M).","Adjusted EBITDA negative $0.5M vs negative $0.2M in Q1 2023; cash $0.7M down from $1.3M.","Acquired Elevated Softgels, a Colorado softgel and tincture manufacturer; no deal terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":4002000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224391,"accession_number":"0000950170-24-058981","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"CV Sciences acquires Elevated Softgels for up to $1M; plans in-sourcing of +PlusCBD production","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to $1,000,000: $100k cash, 17.4M shares ($700k), plus earnout up to $200k.","Elevated Softgels is a GMP-certified, FDA-registered manufacturer of softgels and tinctures.","CEO says acquisition expected to be accretive in first year; softgels and tinctures were ~50% of 2023 sales.","Plans to in-source manufacturing of +PlusCBD branded products for meaningful cost savings.","Earnout thresholds: $200k if net revenue ≥$700k in 12 months, $0 if <$550k, with intermediate steps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243707,"accession_number":"0000950170-24-037652","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences FY2023 revenue $16.0M (flat), gross margin improves to 44.3% from 34.2%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $16.0M for FY2023, flat vs $16.2M in 2022; Q4 revenue $3.8M down 2% YoY.","Gross margin 44.3% (FY2022: 34.2%); operating income $3.4M vs loss $6.8M, helped by $6.2M payroll tax reversal.","Cash $1.3M at year-end; cash from operations $2.3M including $2.5M employee retention credit.","Adjusted EBITDA negative $2.3M in FY2023, improved from negative $6.1M in FY2022.","Acquired Cultured Foods in Q4 2023; launched new products; #1 hemp extract brand in natural retail per SPINS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261106,"accession_number":"0001510964-23-000042","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"CV Sciences acquires Cultured Foods for up to $535K to enter plant-based food market","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to $535K: $175K cash, 7.07M shares valued at $250K, plus up to $110K earn-out.","Cultured Foods (Warsaw, Poland) manufactures plant-based vegan foods sold in 15 European countries.","Acquisition creates European base for PlusCBD™ product distribution and opens US import of plant-based foods.","Expected to be accretive in first year; founder Barbara McWhorter stays as GM.","Deal closed Dec 7, 2023; shares issued unregistered under Section 4(a)(2)/Reg D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261105,"accession_number":"0001510964-23-000036","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q3 revenue $4.1M (+9% YoY); margin expands; signs LOI for European acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.1M, +9% YoY from $3.8M; gross margin 45.1% vs 41.6%.","Operating loss narrowed to $0.4M from $0.9M; adjusted EBITDA -$0.4M vs -$1.2M.","Cash balance $1.6M (up from $0.6M end 2022); operating cash flow $2.4M (incl. $2.5M ERC).","Signed non-binding LOI to acquire a plant-based food company in Europe as part of new M&A strategy.","Maintained #1 hemp extract brand in natural retail; launched PlusCBD Reserve Sleep Gummies."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":12203000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278376,"accession_number":"0001510964-23-000030","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q2 revenue $4.0M; gross margin 43.3%, operating loss narrows to $1.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $4.0M, down 4% YoY from $4.1M; units sold down 16%, offset by higher average selling price.","Gross margin improved to 43.3% vs 30.7% YoY; operating loss narrowed to $1.1M from $2.3M.","Cash balance $1.7M at quarter-end vs $0.6M at FY2022; generated $2.4M cash from operations in H1 2023 (incl. $2.5M ERC).","Extinguished outstanding note payable; evaluating strategic options including merger or sale.","Maintained #1 hemp extract brand in natural product retail channel; launched PlusCBD Reserve Collection Extra Gummies."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":8114000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296528,"accession_number":"0001510964-23-000026","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CV Sciences shareholders approve 2023 Equity Incentive Plan, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2023 Equity Incentive Plan (11.7M for, 8.6M against) to replace 2013 Plan.","Elected directors: Dr. Jamie Corroon, Joseph Dowling, Bill McCorkle to serve until next annual meeting.","Ratified Haskell & White LLP as independent auditor for FY2023 (74.7M for, 1.2M against).","Non-binding advisory vote on named executive officer compensation approved (11.8M for, 8.7M against).","Quorum of 50.4% (76.6M of 152.1M shares) present at virtual annual meeting on June 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296527,"accession_number":"0001510964-23-000022","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q1 revenue down 7% to $4.1M; gross margin improves to 43% vs 26% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.1M vs $4.4M YoY; sequential increase of 7% from Q4 2022.","Gross margin 43.0% vs 26.0% YoY; operating income $5.8M (incl. $6.2M payroll tax reversal).","Adjusted EBITDA loss narrowed to $0.2M from $2.5M YoY; cash balance $0.7M.","Received $2.5M employee retention credit; extinguished outstanding note in Q2 2023.","Maintained #1 hemp extract brand in natural product retail per SPINS; preliminary approval of shareholder derivative lawsuit settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":4148000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316962,"accession_number":"0001510964-23-000012","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences FY2022 revenue $16.2M, down 19% YoY; operating loss narrows to $6.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $16.2M for FY2022 vs $20.0M in 2021 (-19%); Q4 revenue $3.9M, up 3% sequentially.","Gross margin 34.2% in FY2022 vs 43.0% in 2021; Q4 gross margin 40.4%.","Operating expenses cut 54% to $12.4M; operating loss improved to $6.8M from $18.4M.","Cash balance $0.6M at year-end; Q4 generated $0.2M positive operating cash flow.","Regained #1 hemp extract brand in natural retail; launched new products; evaluating M&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316961,"accession_number":"0001510964-23-000003","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CV Sciences reaches preliminary settlement of shareholder derivative action; final hearing May 15, 2023","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for Nevada granted preliminary approval on Feb 7, 2023 for settlement of Lamont v. Mona, Jr. (Case 2:15-cv-00481).","Final approval hearing set for May 15, 2023 before Judge Richard F. Boulware II in Las Vegas.","Settlement requires CV Sciences to implement corporate governance reforms within 60 days of final approval.","Company and defendants deny any liability or wrongdoing; settlement is not an admission.","Plaintiff's counsel may seek an award of attorney's fees; no monetary payment to shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335222,"accession_number":"0001510964-22-000085","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q3 2022 revenue down 27% YoY to $3.8M, operating loss narrowed to $0.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.8M, down 27% from $5.1M; gross margin 41.6% vs 46.2%.","Operating loss improved to $0.9M from $3.0M; negative adjusted EBITDA $1.2M vs $2.7M.","Cash balance $1.1M; extinguished entire outstanding convertible debt.","Preliminary approval of settlement of six shareholder derivative lawsuits; continues strategic review including M&A.","Launched PlusCBD Reserve Collection; maintains #1 hemp extract brand in natural channel per SPINS."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":12336000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335221,"accession_number":"0001510964-22-000079","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2022-10-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CV Sciences appoints William McCorkle as director and Audit Committee chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William McCorkle appointed to Board on Oct 21, 2022; will serve as Chair of Audit Committee.","Receives 500,000 stock options vesting 50% on Oct 21, 2023 and Oct 21, 2024.","Quarterly cash stipend of $5,000 for service on Board and committees.","No related-party transactions or arrangements with any other person in connection with appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352662,"accession_number":"0001510964-22-000076","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2022-09-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CV Sciences reaches preliminary settlement of six derivative lawsuits; court grants approval","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court granted preliminary approval on Sept 21, 2022; final hearing set for Nov 14, 2022.","Settlement includes $275,000 in attorneys' fees to plaintiffs and corporate governance reforms.","Defendants deny all wrongdoing; settlement is not an admission of liability.","Six derivative actions consolidated: Depoti, Radcliffe, Tarangelo, Francis, Berry, Menna."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352661,"accession_number":"0001510964-22-000072","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2022-08-25T23:59:59+00:00","items":["1.01","1.02","7.01","9.01"],"status":"ready","headline":"CV Sciences issues $2M secured note, extinguishes convertible debt to reduce dilution","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered $2M secured promissory note with Streeterville Capital; net proceeds $1.59M after $400K OID and $10K fees.","Terminated existing $1.06M convertible note from 3i, LP by paying $675K settlement amount.","CEO states elimination of convertible debt removes dilutive stock issuance and downward price pressure.","Maturity of new note is 9 months from Aug 19, 2022; accelerated repayment from any CARES Act proceeds received."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352660,"accession_number":"0001510964-22-000065","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q2 2022 revenue falls 19% to $4.1M; gross margin drops to 30.7%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.1M down from $5.1M YoY; units sold decreased 5%.","Gross margin 30.7% vs 44.7% in Q2 2021, hurt by product mix and higher discounts.","Operating loss narrowed to $2.3M from $3.5M; adj. EBITDA loss $1.8M (vs $2.4M).","Cash balance $1.1M at quarter end; OPEX reduced 38.2% YoY.","Regained top hemp extract brand in natural retail per SPINS; strategic review ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":8585000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352659,"accession_number":"0001510964-22-000058","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CV Sciences appoints Dr. Jamie Corroon Jr. to board; Dr. Maroon resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jamie Corroon Jr. appointed to Board of Directors effective July 21, 2022.","Dr. Corroon served on Medical Advisory Board since 2020; background in naturopathic medicine and cannabis.","Dr. Joseph C. Maroon resigned same day; resignation not due to any disagreement with the company.","Dr. Corroon will hold office until next stockholder election of directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370241,"accession_number":"0001510964-22-000051","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2022-06-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CV Sciences resolves note default via conversion; investor converts $152K into 3.75M shares at $0.04","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CV Sciences failed to repay $130K principal plus interest on Nov 2021 senior convertible note at May 17, 2022 maturity, causing default.","On May 18, 2022, company entered a forbearance agreement with investor; deadline to repay with 15% premium was June 1, 2022.","On May 31, investor converted entire outstanding $151,772 (incl. premium & interest) into 3,751,971 shares at $0.04/share, resolving default.","Note terminated; company has no further payment obligations under the note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370240,"accession_number":"0001510964-22-000048","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2022-06-01T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"CV Sciences stockholders approve 4x share increase, reverse split up to 1:400; Board reduced to 3","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stockholders elected Dr. Joseph Maroon and Joseph Dowling as directors; 3 prior directors did not stand for re-election.","Authorized shares increased from 200M to 800M; common stock authorized from 190M to 790M.","Reverse stock split approved (1:10 to 1:400), at Board discretion before May 30, 2025.","Board size reduced to 3 members to cut costs, leaving one vacancy.","Ratification of Haskell & White as auditor for FY2022 passed; advisory vote on executive comp approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370239,"accession_number":"0001510964-22-000045","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2022-05-24T23:59:59+00:00","items":["1.01","2.04","9.01"],"status":"ready","headline":"CV Sciences defaults on $1.06M convertible note; enters forbearance until June 1, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Failed to pay $130K principal plus interest on May 17, 2022 maturity date, triggering default.","Default interest rate of 15% per annum applied; investor can demand redemption at 115% of face value.","Forbearance agreement signed May 18, 2022; investor agrees not to exercise remedies through June 1, 2022 or earlier trigger events.","Company must pay aggregate principal at redemption premium plus all accrued interest and fees after forbearance period.","All other terms of the original note and securities purchase agreement remain in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370238,"accession_number":"0001510964-22-000040","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences Q1 revenue $4.4M (-8% YoY); operating loss narrows to $1.5M on ERC benefit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.4M, down 8% from $4.8M in Q1 2021; units shipped up 3% offset by discounts and mix.","Operating loss narrowed to $1.5M from $3.1M in Q1 2021; included $2.0M employee retention credit.","Gross margin 26.0%, down from 32.4% in Q4 2021 sequentially; pressure from discounts/mix.","Negative adjusted EBITDA $2.5M vs $2.3M a year ago; cash rose to $2.4M from $1.4M.","Strategic review continues for possible merger/sale; launched new PlusCBD and OTC pain products."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":4447000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370237,"accession_number":"0001510964-22-000023","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2022-04-01T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"CV Sciences raises $700K via convertible preferred and warrants; seeks reverse split up to 1:400","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 700 shares of convertible preferred ($1,000 stated value) convertible into 10M shares at $0.07/sh, plus warrants for 10M shares at $0.10/sh.","Gross proceeds $700K; placement agent fees 7.5% plus 1.0% management fee and warrants for 750K shares at $0.0875.","To seek shareholder approval to increase authorized common from 190M to 790M and reverse stock split between 1:10 and 1:400.","Preferred stock has 170,000 votes per share only on the proposals; no other voting rights; dividends on as-converted basis.","Closing occurred March 31, 2022; warrants exercisable after shareholder approval, expire 3 years later; anti-dilution and reset provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389335,"accession_number":"0001510964-22-000016","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2022-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CV Sciences reports FY2021 revenue down 18% to $20.0M; loss narrows to $18.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $20.0M for FY2021, down 18% from $24.4M in 2020.","Gross margin declined to 43.0% from 45.1%; cash fell to $1.4M from $4.5M.","Operating loss improved to $18.4M from $22.6M; adjusted EBITDA negative $10.0M.","Retail distribution expanded to 8,400+ stores from 7,300 as of Dec 31, 2021.","Launched new products; GNC distribution agreement; PPP loan forgiveness of $2.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":4447000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389334,"accession_number":"0001510964-22-000008","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2022-03-28T23:59:59+00:00","items":["1.01","2.03","2.01","8.01","9.01"],"status":"ready","headline":"CV Sciences closes second tranche of $1.06M convertible note issuance, netting ~$950K","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second closing of $1.06M senior convertible notes (6% OID) under existing SPA, net proceeds ~$950K.","Notes convertible into up to $1.06M in common stock; issued via second supplemental indenture.","Remaining $3.18M of $5.3M total offering may be sold in future closings if conditions met.","First closing of $1.06M occurred November 17, 2021; total raised to date $2.12M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407278,"accession_number":"0001510964-21-000087","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2021-12-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CV Sciences enters new employment agreement with CFO Joerg Grasser; base salary $350K with deferred comp","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Term through Dec 26, 2024; Base salary $350K, reduced to $235K plus deferred comp accrual.","Annual bonus target 20% of base salary, discretionary by Board.","Change-of-control bonus: lump sum 2x $350K ($700K).","Severance: without cause or good reason, continuation of salary & benefits through term (min 1 yr); equity vesting accelerates.","Cause or voluntary termination: only unpaid deferred comp and salary through date; no severance; unvested equity forfeited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407274,"accession_number":"0001510964-21-000085","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K/A","filed_at":"2021-12-01T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"CV Sciences amends 8-K to correct Deloitte & Touche letter error in Exhibit 16.1","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment replaces Exhibit 16.1 due to an error in the Deloitte & Touche LLP letter originally filed on Nov 30, 2021.","No other changes were made to the original Form 8-K.","The original 8-K likely related to a change in auditors or an accounting disagreement.","This correction has no effect on the company's financial statements or operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407277,"accession_number":"0001510964-21-000082","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2021-11-30T23:59:59+00:00","items":["4.01","7.01","9.01"],"status":"ready","headline":"CV Sciences dismisses Deloitte, appoints Haskell & White as new auditor to reduce costs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Deloitte & Touche and engaged Haskell & White as independent auditor effective November 30, 2021.","Change approved by Audit Committee to reduce ongoing annual audit costs.","No disagreements with Deloitte on accounting principles; only reportable event was a remediated material weakness from 2018.","Deloitte's reports on FY 2020 and 2019 financials were unqualified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407276,"accession_number":"0001510964-21-000075","cik":1510964,"company_name":"CV Sciences, Inc.","ticker":"CVSI","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"CV Sciences enters $5.3M convertible note facility; initial close of $1.06M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial closing of $1.06M principal (6% OID) yields ~$850K net proceeds; up to $5.3M aggregate available.","Notes mature 6 months from issuance (May 17, 2022); convertible at $0.2611/share with full-ratchet anti-dilution.","Interest accrues at 15% upon default; various redemption and alternate conversion options included.","Additional closings conditioned on share price >$0.15, minimum trading volume, and filing of new supplements.","Company issued press release on Nov 15, 2021, announcing the signing of the securities purchase agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5389086.566153846,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-15T23:59:59+00:00|407276"}